Head-to-head evidence
Iloperidone (PD psychosis use) vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (PD psychosis use) · Fanapt
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
The trial was randomized and quadruple-blind, included both placebo and active control groups, and enrolled 593 participants. Its primary clinical symptom endpoint was PANSS-T change, with mean changes of -12.0 for iloperidone versus -7.1 for placebo, but statistical significance of the comparison is not reported, so the result remains unclear.
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Risperidone (Risperdal)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
The study randomized 458 participants to double-blind risperidone or placebo, with change in the clinical PANSS score as the primary endpoint. Because the registry does not report whether this endpoint was met, the trial provides a well-controlled design but no assessable result.
Next expected readout: December 2026 · NCT06482554 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (PD psychosis use)'s landscape · Risperidone (Risperdal)'s landscape